Rapport Therapeutics (RAPP) Gains Wells Fargo Endorsement with Significant Upside Potential

Wells Fargo initiated coverage of Rapport Therapeutics (RAPP) on February 2, 2026, assigning an Overweight recommendation to the biotech company. This bullish stance reflects growing confidence in the company’s pipeline and commercial prospects, positioning RAPP shares for substantial potential appreciation.

Analyst Price Forecast Signals Strong Valuation Runway

Analysts tracking Rapport Therapeutics have established an average one-year price target of $53.30 per share, representing a projected 91.50% upside from the stock’s latest closing price of $27.83. The forecast range spans from a conservative $40.40 to an optimistic $84.00, reflecting varying analyst perspectives on the company’s growth trajectory. This substantial price target premium positions RAPP among securities with the most compelling upside potential in the biopharma sector.

Notably, the projected annual non-GAAP earnings per share stands at -3.36, indicating that RAPP remains in a pre-profitability phase typical of development-stage therapeutics companies. Nevertheless, analyst recommendations emphasize long-term value creation potential.

Institutional Investors Accelerate Portfolio Additions

The institutional investment landscape for RAPP shows robust momentum. A total of 210 funds and institutions reported positions in Rapport Therapeutics as of January 14, 2026, marking an increase of 5 new owners—a 2.44% jump from the previous quarter. More significantly, average portfolio weight across these funds dedicated to RAPP surged by 35.58%, reaching 0.66% of their average holdings. Aggregate institutional shareholding grew 25.96% to 51,351 thousand shares over the trailing three-month period.

The put/call ratio for RAPP stands at 0.15, a notably low level that signals bullish market sentiment and investor confidence in the company’s near-term prospects.

Major Shareholders Expand Stakes in Therapeutic Play

Several large investors have meaningfully increased their RAPP allocations. Goldman Sachs Group executed the most aggressive expansion, nearly doubling its position from 1,235 thousand shares to 2,422 thousand shares—a 49.01% quarterly increase that inflated its portfolio allocation by 361.31%. This major financial institution now holds 5.08% of RAPP’s outstanding shares.

Capital International Investors similarly ramped up exposure, adding 800 thousand shares to reach 3,403 thousand shares (7.14% ownership), representing a 23.51% addition and a 220.10% increase in portfolio weighting. Cormorant Asset Management boosted holdings by 252 thousand shares to 3,193 thousand shares (6.70% ownership), reflecting a 7.88% increase and a 162.67% portfolio allocation expansion.

Leading venture capital backers maintain stable positions: Trv Gp V controls 7,135 thousand shares (14.97% ownership) with no change, while Arch Venture partners holds 3,729 thousand shares (7.82% ownership) with no recent adjustment.

Market Outlook for RAPP Therapeutic Pipeline

The combination of Wells Fargo’s newly initiated Overweight rating, substantial analyst upside targets exceeding 90%, accelerating institutional buying, and bullish options market signals creates a compelling investment thesis for Rapport Therapeutics. The therapeutic company’s ability to attract major institutional capital alongside positive analyst sentiment underscores market confidence in its clinical and commercial trajectory, positioning RAPP as a dynamic story in the biopharma space.